• 4-Hydroxytamoxifen (B6167) Workflow Guide

  2026-10-01

  4-Hydroxytamoxifen (B6167) is an estrogen receptor modulator for controlled DMSO-based workflows in breast cancer research, prostate cancer research, and cardiac myocyte studies. It should not be selected for protocols requiring aqueous or ethanol solubility, and the dossier does not establish a validated dose, schedule, or efficacy protocol.

• Partial BACE Inhibition and Synaptic Transmission

  2026-10-01

  Satir et al. examined whether partial β-secretase inhibition can lower amyloid-β secretion without disrupting neuronal communication. Using primary cortical neurons, optical electrophysiology, and three BACE inhibitors, the study identified a functional exposure range in which amyloid beta reduction remained below approximately 50% and synaptic transmission was preserved.

• DNMT3B and Neuroendocrine Prostate Cancer Plasticity

  2026-09-30

  The reference study identifies DNMT3B as a driver of therapy-associated neuroendocrine lineage plasticity and stemness in prostate cancer. Genetic and pharmacologic experiments indicate that suppressing DNMT3B reduces neuroendocrine prostate cancer growth, alters differentiation programs, and promotes apoptosis, providing a rationale for further translational investigation.

• Fulvestrant (ICI 182,780) ER Research Guide

  2026-09-30

  Explore how Fulvestrant (ICI 182,780) supports ERα degradation studies, MDM2 protein degradation research, and chemotherapy-sensitization workflows. This guide also shows how to adapt the compound as a mechanistic control in estrogen–immune signaling assays while avoiding unsupported cross-domain conclusions.

• Multiomics of Crossbreeding and Goose Meat Quality

  2026-09-29

  The reference study combined RNA-seq and nontargeted metabolomics to examine how crossbreeding and sex shape growth, carcass traits, and meat quality in Xingguo gray geese. Its integrated analysis connected production phenotypes with muscle-development and lipid-metabolism signals, providing a molecular framework for interpreting crossbred performance beyond conventional carcass measurements.

• Foretinib (GSK1363089) Research Workflows

  2026-09-29

  Build stronger Foretinib assays by separating tumor cell growth inhibition from true cell killing and by pairing proliferation, motility, invasion, and metastasis endpoints. This workflow combines dose-controlled in vitro experiments with translational guidance for cancer metastasis models and ovarian cancer xenograft studies.

• (S)-(+)-Ibuprofen COX Inhibition Workflows

  2026-09-28

  Build reproducible COX inhibition, inflammation pathway research, and pain mechanism study workflows with the pharmacologically active ibuprofen enantiomer. This guide connects concentration planning, solvent control, assay troubleshooting, and environmental toxicology considerations for more defensible results.

• Foretinib (GSK1363089): Reliable Cell Assays

  2026-09-28

  A practical guide to using Foretinib (GSK1363089), SKU A2974, in cell viability, proliferation, and motility studies. It connects kinase potency and product handling data with scenario-based assay design and interpretation.

• Pazopanib Hydrochloride: Better In Vitro Drug Responses

  2026-09-27

  Use Pazopanib Hydrochloride to probe multi-kinase and anti-angiogenic responses—but distinguish slowed growth from actual cell killing. A paired, time-resolved workflow helps identify which effect your model captures and avoids overinterpreting a single viability endpoint.

• EX 527: Testing SIRT1 in Bone Regeneration

  2026-09-26

  Use EX 527 (SEN0014196) to test whether SIRT1 catalytic activity is necessary for vascular and osteogenic phenotypes—not simply to assume that inhibition reverses activation. This workflow connects p53 acetylation and DNA damage response assays with carefully controlled endothelial–osteogenic experiments.

• Partial BACE Inhibition Preserves Synaptic Transmission

  2026-09-25

  Satir et al. tested whether reducing amyloid-β (Aβ) production with β-secretase inhibitors necessarily disrupts neuronal communication. In cultured rat cortical neurons, Aβ secretion could be reduced by less than 50% without a detectable decrease in synaptic transmission, whereas stronger inhibition was associated with reduced transmission—supporting a dose-sensitive, rather than all-or-none, view of BACE1 inhibition.

• Caspase-3–NDUFS1 Signaling in Trichothecene Liver Injury

  2026-09-25

  A not-yet-peer-reviewed preprint proposes that caspase-3 amplifies trichothecene-induced oxidative stress by cleaving mitochondrial complex I subunit NDUFS1, while ER oxidoreductase ERO1α contributes a second ROS source. The findings connect mitochondrial injury with ER redox stress and suggest experiments that should combine pathway-specific molecular measurements with functional mitochondrial readouts.

• 4-Phenylbutyric Acid: Reading ER Stress Rescue

  2026-09-24

  Discover how 4-Phenylbutyric acid (4-PBA) can help test whether ER stress contributes to cancer-cell death—not merely whether stress markers change. This evidence-led guide translates a liver-cancer study into practical assay design, interpretation, and controls for autophagic cell death research.

• U-73122 in Cancer Invasion: Interpreting PLC Evidence

  2026-09-24

  Learn how U-73122 can test phospholipase C involvement in breast cancer cell invasion without overstating what inhibitor data prove. This guide connects the QPRT study to practical assay design, pathway readouts, and reagent handling.

• Nebivolol Hydrochloride as a TOR Assay Control

  2026-09-23

  Nebivolol hydrochloride is a selective β1-adrenoceptor antagonist, but a 2025 drug-sensitized yeast study found no evidence that it inhibited TOR in that model. This article explains how to interpret that result, use it as a conditional negative comparator, and keep cardiovascular and TOR assay conclusions distinct.

7771 records 1/519 page Next 12345 下5页 Last page